The Cell and Gene Therapy Working Group was established in 2023 through the merger of the Cell Therapy Working Group and Gene Therapy Working Group. This regulator-only working group allows for the discussion of topics where regulatory policy is under development, with a focus on convergence of regulatory approaches within the confines of national regulations for advanced therapies.
- ANMAT, Argentina
- ANVISA, Brazil
- COFEPRIS, Mexico
- CPED, Israel
- EDA, Egypt
- EMA, European Commission
- FDA, United States
- HC, Canada
- HSA, Singapore
- ISPCH, Chile
- MHLW/PMDA, Japan
- MFDS, Republic of Korea
- MHRA, United Kingdom
- MOH, Indonesia
- NPRA, Malaysia
- SAPHRA, South Africa
- SFDA, Saudi Arabia
- Swissmedic, Switzerland
- TGA, Australia
- TFDA, Chinese Taipei
- Thai FDA, Thailand
- TITCK, Türkiye
Observers:
- PAHO/PANDRA
- WHO
The Cell and Gene Therapy Working Group is a regulator-only working group with the following objectives:
-
Provide an open forum for discussion of cell and gene therapy products.
-
Retain knowledge of regulatory activities in participating regions
-
Identify Topics for regulatory convergence or harmonization.
-
When appropriate, propose topics to ICH for harmonisation
Products under discussion:
- Cell therapy products:
- Gene-modified cells
- Viral vectors
- Oncolytic vectors
- Genetically modified bacterial vector-based gene therapy products
- Genome editing technologies
- Tissue engineered products
- Xenotransplantation products
Key Deliverables:
-
Post results of working group projects
-
Draft reflection papers on topics with potential for convergence or harmonization
-
Publish journal articles and white papers, when appropriate
-
Update information on the regulatory landscape of cell and gene therapy products (Framework Project)
The working group has an on-going project, “Framework Project” which consists of a list of regulations, guidance documents, reflection papers and guidelines, and a list of approved products in participating regions. This project will be updated as needed and is considered a living document.